Richard E. Chaisson, MD
Infectious Diseases
Highlights
Johns Hopkins Affiliations:
- Johns Hopkins School of Medicine Faculty
About Richard E. Chaisson
Professional Titles
- Director, Center for Tuberculosis Research
- Director and Principal Investigator, Center for AIDS Research
Primary Academic Title
Professor of Medicine
Background
Dr. Richard E. Chaisson is a professor of medicine at the Johns Hopkins University School of Medicine. He holds joint appointments in epidemiology and in international health, both in the Johns Hopkins Bloomberg School of Public Health. His area of clinical expertise is infectious diseases, particularly tuberculosis and HIV/AIDS.
Dr. Chaisson serves as the director of the Johns Hopkins University Center for Tuberculosis Research, and is the director of the Johns Hopkins Center for AIDS Research.
He received his B.S. and M.D. degrees from the University of Massachusetts. He was an intern, resident, fellow and assistant professor of medicine at the University of California, San Francisco, prior to moving to Johns Hopkins.
From 1988 to 1998 he was director of the Johns Hopkins AIDS Service, leading the inpatient Polk Service on Osler 8, a subacute care unit at Bayview Medical Center, and the outpatient Moore Clinic. His cohort studies of HIV and with his colleague Richard Moore made major contributions to understanding the treatment and outcomes of HIV disease. In 1991 he was appointed Medical Director of the Baltimore City Health Department Tuberculosis Clinic, establishing it as a leading program in TB control. He founded the Center for TB Research in 1998, which is one of the world's leading academic center for basic, clinical, applied, and epidemiologic investigations in TB and its control.
Dr. Chaisson has conducted multiple trials of treatments and strategies to treat, prevent, and control TB, TB/HIV co-infection, and HIV. From 2002-2014 he led the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), and from 2011-2018 he was inaugural chair of the TB Transformative Science Group of the AIDS Clinical Trials Group. In 2022 he was awarded a $200 million cooperative agreement from USAID for SMART4TB, an international research consortium to study tools to end TB globally, working with partners from multiple institutions to implement research, strengthen local capacity, and drive policy change.
Dr. Chaisson has been recognized with numerous honors, including the HIV/AIDS Warrior Award from AIDS Action Baltimore in 2022, a Lifetime Achievement Award from the International Union Against TB and Lung Disease North American Region in 2021, election to the Association of American Professors in 2016, the Champions of TB Control Award from the U.S. Agency for International Development (USAID) in 2014 and the American Thoracic Society's World Lung Health Award in 2006.
Centers and Institutes
Clinical Trial Keywords
Tuberculosis; Tuberculosis screening; HIV-infected pregnant women; HIV-infected Malawians; HIV-associated lung infections and complications
Lab Website
Richard Chaisson Lab
- Research in the Richard Chaisson Lab primarily examines tuberculosis and HIV infection, with specific focus on global epidemiology, clinical trials, diagnostics and public health interventions. Our recent research has involved evaluating a molecular diagnostic test for tuberculosis in HIV patients; observing TB responses during treatment of pulmonary tuberculosis; and examining antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in Southern Africa.
Research Summary
Dr. Chaisson’s research focuses on tuberculosis and HIV infection, including global control, prevention, clinical trials and public health interventions. He leads research projects in multiple countries.
He serves as the principal investigator of numerous research grants and of the SMART4TB Consortium.
Selected Publications
Dorjee K, Topgyal S, Tsewang T, Tsundue T, Namdon T, Bonomo E, Kensler C, Lhadon D, Choetso T, Nangsel T, Dolkar T, Tsekyi T, Dorjee C, Phunkyi D, Sadutshang TD, Paster Z, Chaisson RE. Risk of developing active tuberculosis following tuberculosis screening and preventive therapy for Tibetan refugee children and adolescents in India: An impact assessment. PLoS Med. 2021PLoS Med 18(1):e1003502. https://doi.org/10.1371/journal.pmed.1003502
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Wiener M, Swindells S, Chaisson RE, for the AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021, 384:1705-18. PMCID: PMC8282329.
Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20. PMCID: PMC3407678.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155-66. PMID: 22150035.
Swindells S, Ramchandani aakR, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L , Andersen J, Fletcher CV, Nuermberger E, Chaisson RE, for the ACTG A5279/BRIEF TB Study Team. One Month of Rifapentine and Isoniazid to Prevent HIV-related Tuberculosis. N Engl J Med, 2019;380:1001-11. PMCID: PMC6563914.
Courses & Syllabi
- Epidemiologic Basis for Tuberculosis Control, Department of Epidemiology, 340.612.01, 1/1/96
- Epidemiologic Basis for Tuberculosis Control, Department of Epidemiology, 340.612.81, 1/1/15
Honors
- HIV/AIDS Warrior Award, AIDS Action Baltimore, 9/18/22
- Champions of TB Control Award, U.S. Agency for International Development (USAID), 1/1/14
- Charles C. Shepard Science Award, Centers for Disease Control and Prevention, 1/1/12
- Dr. David Glasser Memorial Tuberculosis Control and Prevention Award, Maryland Department of Health and Mental Hygiene, 1/1/08
- World Lung Health Award, American Thoracic Society, 1/1/06
Locations
- The Johns Hopkins Hospital
- 1800 Orleans Street, Baltimore, MD 21287
- phone: 410-955-5000
- fax: 410-955-5001
Expertise
Education
UCSF Medical Center
Fellowship, 1987UCSF Medical Center
Residency, Internal Medicine, 1985University of Massachusetts Chan Medical School
Medical Education, MD, 1982Board Certifications
Internal Medicine
American Board of Internal Medicine, 1985Insurance
- Aetna
- CareFirst
- Cigna
- First Health
- Geisinger Health Plan
- HealthSmart/Accel
- Humana
- Johns Hopkins Health Plans
- MultiPlan
- Pennsylvania's Preferred Health Networks (PPHN)
- Point Comfort Underwriters
- Private Healthcare Systems (PHCS)
- UnitedHealthcare
- Veteran Affairs Community Care Network (Optum-VACCN)